ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VRCI Verici Dx Plc

8.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Verici Dx Plc LSE:VRCI London Ordinary Share GB00BM8HZD43 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.00 7.50 8.50 8.00 8.00 8.00 295 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 0 -11.41M -0.0670 -1.79 20.44M

Verici Dx PLC Result of General Meeting

19/02/2024 12:35pm

RNS Regulatory News


RNS Number : 6453D
Verici Dx PLC
19 February 2024
 

Verici Dx plc

("Verici Dx" or the "Company")

 

Result of General Meeting

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the general meeting held earlier today (the "GM"), all the resolutions, as set out in the notice of the GM published on 26 January 2024, were duly passed. Resolution 1 was passed as an ordinary resolution and resolution 2 was passed as a special resolution.

 

The voting results of the GM were as follows:

 


In Favour

Against

Withheld

Resolution

Votes

%

Votes

%

Votes

1

68,286,823

99.86

93,862

0.14

13,812

2

68,270,191

99.84

110,494

0.16

13,812

 

 

Enquiries:

 

Verici Dx

www.vericidx.com

Sara Barrington, CEO

Via IR-Connect

Julian Baines, Chairman

 



Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 20 7496 3000

Aubrey Powell / Sam Butcher/ Jalini Kalaravy




IR-Connect

 www.ir-connect.co.uk

Lorraine Rees

investors@vericidx.com

 

 

About Verici Dx plc www.vericidx.com

Verici is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMGPUCWPUPCGPB

1 Year Verici Dx Chart

1 Year Verici Dx Chart

1 Month Verici Dx Chart

1 Month Verici Dx Chart

Your Recent History

Delayed Upgrade Clock